Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia

This study explored the relative efficacy of ibrutinib versus previous standard-of-care treatments in relapsed/refractory patients with chronic lymphocytic leukaemia (CLL), using multivariate regression modelling to adjust for baseline prognostic factors. Individual patient data were collected from...

Descripción completa

Detalles Bibliográficos
Autores principales: Hansson, Lotta, Asklid, Anna, Diels, Joris, Eketorp-Sylvan, Sandra, Repits, Johanna, Søltoft, Frans, Jäger, Ulrich, Österborg, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569664/
https://www.ncbi.nlm.nih.gov/pubmed/28762081
http://dx.doi.org/10.1007/s00277-017-3061-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569664/
https://www.ncbi.nlm.nih.gov/pubmed/28762081
http://dx.doi.org/10.1007/s00277-017-3061-3

Ejemplares similares